|
gptkbp:instanceOf
|
gptkb:drug
gptkb:antihistamine
gptkb:phenothiazine_derivative
|
|
gptkbp:approvalYear
|
1951
|
|
gptkbp:approvedBy
|
US
|
|
gptkbp:ATCCode
|
R06AD02
|
|
gptkbp:availableOn
|
gptkb:sugar
gptkb:tablet
injectable solution
suppository
|
|
gptkbp:brand
|
gptkb:Phenergan
gptkb:Promethegan
Phenadoz
|
|
gptkbp:CASNumber
|
60-87-7
|
|
gptkbp:contraindication
|
children under 2 years
hypersensitivity to promethazine
|
|
gptkbp:discoveredBy
|
gptkb:Laboratoires_Rhône-Poulenc
|
|
gptkbp:discoveredIn
|
1946
|
|
gptkbp:eliminationHalfLife
|
10-19 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C17H20N2S
|
|
gptkbp:interactsWith
|
gptkb:MAO_inhibitors
gptkb:CNS_depressants
anticholinergic drugs
|
|
gptkbp:legalStatus
|
prescription only (US)
|
|
gptkbp:mechanismOfAction
|
H1 receptor antagonist
anticholinergic effects
weak dopamine antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
rectal
|
|
gptkbp:sideEffect
|
confusion
constipation
dizziness
blurred vision
drowsiness
respiratory depression
dry mouth
|
|
gptkbp:usedFor
|
nausea
vomiting
cough
sedation
motion sickness
allergy symptoms
preoperative anxiety
|
|
gptkbp:bfsParent
|
gptkb:C17H20N4S
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
promethazine
|